Enhance your practice with CME and tools that focus on diseases and conditions impacting the female patient.
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
Aditya Bardia, MD, MPH, FASCO
Rapid Data Pulses From ASCO 2026: Emerging Data on Oral Targeted Strategies in Breast Cancer
Erica L. Mayer, MD, MPH
22nd Annual Women’s Health Annual Visit (WHAV)
December 04, 2026
New York, New York
Shared Goals, Shared Gains: Align With Patient Preferences
Christyn Edmundson, MD
Gil I. Wolfe MD, FAAN
Escalate With Intention: Stepwise, Target-Anchored Moves
The 2-Point Signal: Apply ≥2-Point Rule
The IgG Clock: Redose Using IgG Kinetics
When to Begin FcRn: Initiation Criteria, Key Evidence
November 13, 2026 Pasadena, California
FcRn: Same Class, Different Paths—Spot Agent Differentiators
Treat. Target. Transform: Applying Treat-to-Target Principles in the Management of Generalized Myasthenia Gravis (gMG)
Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT): Overcoming Diagnostic and Therapeutic Challenges
Karin J. Blakemore, MD
Emilie L. Vander Haar
The Alloimmune Disorders of Pregnancy
Capturing the Impact of Endometriosis on Health-Related QoL: The Role of Patient Questionnaires
Lee P. Shulman, MD, FACMG, FACOG
Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP
Early Diagnosis: Its Pivotal Role in Optimizing Outcomes in Patients With Endometriosis – Psychosocial and Physical Consequences
Linda Bradley, MD
Samantha Denäe
The Integral Role of GnRH Antagonists in the Management of Endometriosis
Sawsan As-Sanie, MD
James A. Simon, MD, CCD, NCMP, IF, FACOG
From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
Target Locked in gMG: Why T2T Matters
Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
Turning Flares Into Function: Flag Uncontrolled Disease
It’s Not Just Black and White: Seeing the Full Spectrum of Endometriosis Cases
Melissa Simon, MD
Casey Joe Hinds
Changing the Paradigm in the Management of Endometriosis: Moving Away From “Surgery First” to “Pharmacologic Therapy First”
Pre- and Postoperative Use of GnRH Antagonists
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
Minimal By Design: Define MSE Endpoints
Strategies to Address Healthcare Disparities in Patients With Endometriosis
Can We Talk? Optimizing Patient Buy-In to the Management of Endometriosis
Changing the Mindset in the Management of Endometriosis: Hitting the Pause Button on Surgical Procedures and Expanding the Role of GnRH Antagonists
Parallels Between Kidney Transplantation and Maternal Anti-Fetal Rejection
Alexandra Benachi, MD, PhD
Julien Zuber, MD, PhD
Alloimmune Thrombocytopenia in the Fetus and Newborn
James B. Bussel, MD
Red Blood Cell Alloimmunization, Pathophysiology, Diagnosis, Treatment, and Prevention
Kenneth J. Moise Jr., MD
Loading...
We're glad to see you're enjoying Omnia Education… but how about a more personalized experience?
Press cancel to remain on Omnia Education. Press the link below or the continue button to keep going.